Pfizer (PFE) AI Stock Analysis

• Market Cap: $136.68B
• Dividend Yield: 7.25%
• Average Volume (3M): 42.34M
• Price to Earnings (P/E): 12.8
• Beta (1Y): 0.34
• Revenue Growth: 14.72%
• EPS Growth: N/A
• Country: US
• Employees: 81,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.78
• Shares Outstanding: 5,685,550,300
• 10 Day Avg. Volume: 53,307,601
• 30 Day Avg. Volume: 42,344,070
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.37
• Enterprise Value/Revenue: 2.93
• Enterprise Value/Gross Profit: 4.35
• Enterprise Value/Ebitda: 8.21
• 1Y Price Target: $28.53
• Price Target Upside: 20.89% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 17

• Rating: 73 Outperform
• Price Target: $27.00 ▲(14.41% Upside)

Pfizer's overall stock score is driven by strong financial performance and positive earnings call sentiment, indicating robust profitability and strategic advancements. However, bearish technical indicators and competitive pressures in key segments present challenges. The attractive dividend yield supports valuation, but increasing debt and market pressures warrant caution.

Positive Factors

R&D Advancements

Pfizer's strong R&D advancements, particularly in oncology, position it to capture significant market opportunities and drive long-term growth.

Revenue Growth

Robust demand for key products like Vyndaqel and Padcev indicates strong market positioning and potential for sustained revenue growth.

Cost Management

Effective cost management enhances Pfizer's operating margins, contributing to improved profitability and financial flexibility over time.

Negative Factors

Competitive Pressures

Intensified competition in the oncology sector could limit Pfizer's market share and growth potential in this critical therapeutic area.

Regulatory Challenges

New regulations on pharma ads could impact Pfizer's marketing strategies, potentially affecting sales and brand perception in the long term.

Debt Levels

Rising debt levels may strain Pfizer's cash flow and limit its ability to invest in growth opportunities, impacting long-term financial stability.

Pfizer Business Overview & Revenue Model

Company Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

How the Company Makes Money

Pfizer generates revenue primarily through the sale of prescription medicines and vaccines. The company's revenue model is largely driven by its extensive portfolio of patented drugs, which allows it to charge premium prices. Key revenue streams include sales from its innovative therapies, as well as established brands that continue to perform well in the market. Pfizer also earns revenue from collaborations and partnerships, such as its alliance with BioNTech for the development of the COVID-19 vaccine, which significantly boosted its earnings. Additionally, Pfizer benefits from licensing agreements and royalties associated with its research and development efforts. The company's ability to navigate patent expirations and introduce new products is critical for sustaining its revenue growth.

Pfizer Financial Statement Overview

Summary

Pfizer demonstrates strong financial health across its income statement, balance sheet, and cash flow statement. The company shows solid profitability and cash generation, with manageable leverage levels. While there are some concerns about increasing debt and slight operational efficiency pressures, the overall financial position remains strong, supporting continued growth and stability.

Income Statement

Pfizer's income statement shows strong profitability with a gross profit margin of 74.09% and a net profit margin of 16.83% for the TTM period. Revenue growth is positive at 2.19%, indicating a recovery from previous declines. The EBIT and EBITDA margins are healthy at 15.14% and 27.78%, respectively, reflecting efficient operations. However, the decline in EBIT margin from the previous year suggests some pressure on operational efficiency.

Balance Sheet

The balance sheet is solid with a debt-to-equity ratio of 0.70, indicating a manageable level of leverage. Return on equity is 11.95%, showing decent profitability relative to shareholder equity. The equity ratio stands at 43.03%, suggesting a strong equity base. However, the increase in total debt over the years could pose a risk if not managed carefully.

Cash Flow

Pfizer's cash flow statement is robust, with a free cash flow growth rate of 10.86% in the TTM period. The operating cash flow to net income ratio is 0.40, and the free cash flow to net income ratio is 0.82, indicating strong cash generation relative to earnings. The company has improved its free cash flow position significantly, enhancing financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	63.83B	63.63B	59.55B	100.33B	81.29B	41.65B
Gross Profit	42.99B	41.85B	30.34B	62.09B	46.88B	29.88B
EBITDA	22.77B	18.13B	9.56B	41.03B	30.79B	13.17B
Net Income	10.73B	8.02B	2.13B	31.36B	22.15B	9.16B
Balance Sheet
Total Assets	206.09B	213.40B	226.50B	197.21B	181.48B	154.23B
Cash, Cash Equivalents and Short-Term Investments	13.25B	20.48B	12.69B	22.73B	31.07B	12.22B
Total Debt	61.80B	63.65B	70.84B	34.86B	37.00B	38.27B
Total Liabilities	117.08B	124.90B	137.21B	101.29B	104.01B	90.76B
Stockholders Equity	88.69B	88.20B	89.01B	95.66B	77.20B	63.24B
Cash Flow
Free Cash Flow	12.44B	9.84B	4.79B	26.03B	29.87B	11.61B
Operating Cash Flow	15.19B	12.74B	8.70B	29.27B	32.58B	14.40B
Investing Cash Flow	3.54B	2.65B	-32.28B	-15.78B	-22.55B	-4.27B
Financing Cash Flow	-18.17B	-17.14B	26.07B	-14.83B	-9.82B	-9.65B

Pfizer Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 23.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFE, the sentiment is Negative. The current price of 23.6 is below the 20-day moving average (MA) of 24.35, below the 50-day MA of 24.52, and below the 200-day MA of 24.19, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 37.33 is Neutral, neither overbought nor oversold. The STOCH value of 25.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PFE.

Pfizer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JNJ	80 Outperform	425.53B	18.90	28.88%	2.86%	4.69%	34.88%
NVS	78 Outperform	232.75B	17.69	22.91%	3.27%	12.38%	-12.67%
MRK	75 Outperform	199.00B	12.28	33.49%	4.18%	2.00%	20.01%
PFE	73 Outperform	$136.68B	12.79	12.16%	7.25%	14.72%	―
AMGN	69 Neutral	150.32B	22.84	89.11%	3.46%	13.10%	110.67%
ABBV	68 Neutral	388.63B	104.69	-2059.56%	2.96%	6.05%	-29.75%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%